Abstract
The treatment of metastatic castration-resistant prostate cancer has evolved since the approval of docetaxel-based therapy. Since docetaxel approval, three new agents have gained approval for this indication: sipuleucel-T, cabazitaxel, and abiraterone. Recent Phase III trials have also demonstrated survival benefits for MDV-3100 and radium-223 though regulatory approval ispending. Practicing physicians face the challenge of determining the optimal sequencing of these new agents. This dilemma is particularly relevant to the post-docetaxel setting, in which the indication for several of these agents overlaps. This article details the efficacy and safety of these agents to provide a framework for their clinical use.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Androstenes
-
Androstenols / pharmacology
-
Androstenols / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Docetaxel
-
Humans
-
Male
-
Neoplasms, Hormone-Dependent
-
Nitriles
-
Phenylthiohydantoin / analogs & derivatives
-
Phenylthiohydantoin / pharmacology
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / secondary
-
Radium / therapeutic use
-
Receptors, Androgen / drug effects
-
Steroid 17-alpha-Hydroxylase / drug effects
-
Taxoids / administration & dosage
-
Taxoids / chemistry
-
Taxoids / therapeutic use*
-
Treatment Failure
Substances
-
Androstenes
-
Androstenols
-
Antineoplastic Agents
-
Benzamides
-
Nitriles
-
Receptors, Androgen
-
Taxoids
-
Docetaxel
-
Phenylthiohydantoin
-
cabazitaxel
-
enzalutamide
-
Steroid 17-alpha-Hydroxylase
-
abiraterone
-
Radium